Advisor Net Financial, Inc Kodiak Sciences Inc. Transaction History

Advisor Net Financial, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 14, 2022	SELL	$7.09 - $89.45 $31,834 - $401,630	-4,490 Closed	0 $0
Q4 2021 Jan 19, 2022	BUY	$80.85 - $128.49 $2,991 - $4,754	37 Added 0.83%	4,490 $381,000
Q3 2021 Oct 15, 2021	BUY	$81.97 - $106.94 $6,229 - $8,127	76 Added 1.74%	4,453 $427,000
Q2 2021 Jul 06, 2021	BUY	$77.2 - $126.54 $26,248 - $43,023	340 Added 8.42%	4,377 $407,000
Q1 2021 Apr 14, 2021	SELL	$110.45 - $164.47 $1,767 - $2,631	-16 Reduced 0.39%	4,037 $458,000
Q4 2020 Feb 04, 2021	SELL	$60.78 - $154.03 $1,944 - $4,928	-32 Reduced 0.78%	4,053 $595,000
Q3 2020 Nov 06, 2020	BUY	$45.05 - $59.27 $5,766 - $7,586	128 Added 3.23%	4,085 $242,000
Q1 2020 May 14, 2020	BUY	$38.18 - $73.95 $14,126 - $27,361	370 Added 10.32%	3,957 $189,000
Q4 2019 Feb 12, 2020	BUY	$13.9 - $76.65 $43,368 - $239,148	3,120 Added 668.09%	3,587 $258,000
Q3 2019 Oct 23, 2019	BUY	$10.24 - $17.57 $4,782 - $8,205	467 New	467 $7,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $417M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Advisor Net Financial, Inc, based on Form 13F filings with the SEC.

Stay updated on Advisor Net Financial, Inc with notifications on news.